Hamster CHO CTSA ELISA Kit

Circulating tumor DNA (ctDNA), often assessed through Circulating Tumor Analysis (CTA), refers to small fragments of tumor-derived DNA that are shed into the bloodstream from cancer cells undergoing apoptosis, necrosis, or active secretion. As a biomarker, ctDNA provides a minimally invasive method to capture real-time molecular information about a tumor, reflecting its genetic heterogeneity and evolution over time. Unlike traditional tissue biopsies, which provide a snapshot from a single tumor region, CTA can detect mutations, copy number variations, and methylation changes across multiple tumor sites through a simple blood draw.

In research settings, CTA is extensively used to study tumor dynamics, resistance mechanisms, and treatment response. By sequencing or profiling ctDNA, researchers can identify actionable mutations, monitor clonal evolution, and investigate minimal residual disease (MRD) following therapy. CTA enables longitudinal monitoring of patients in clinical trials, helping to assess drug efficacy and understand mechanisms of relapse or resistance at a molecular level.

In clinical practice, CTA is emerging as a powerful tool for early detection, prognosis, and treatment monitoring. Clinicians use ctDNA-based assays (such as liquid biopsies) to guide targeted therapy selection, detect recurrence before radiographic evidence, and evaluate treatment response in real time. Its noninvasive nature makes it particularly valuable for patients where tissue biopsy is impractical or risky. As technology advances and sensitivity improves, CTA is increasingly integrated into precision oncology workflows, bridging molecular research with clinical decision-making.

This product is manufactured in USA by Eagle Biosciences.